Kevan Herold - Publications

Yale University, New Haven, CT 
Medicine and Surgery, Cell Biology

85 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Garyu JW, Uduman M, Stewart A, Rui J, Deng S, Shenson J, Staron MM, Kaech SM, Kleinstein SH, Herold KC. Characterization of diabetogenic CD8+ T cells: immune therapy with metabolic blockade. The Journal of Biological Chemistry. PMID 26994137 DOI: 10.1074/jbc.M115.713362  0.52
2016 Rui J, Deng S, Lebastchi J, Clark PL, Usmani-Brown S, Herold KC. Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice. Diabetologia. PMID 26910463 DOI: 10.1007/s00125-016-3897-4  0.52
2015 Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K, Ehlers MR, McNamara JG, Harris KM, Kanaparthi S, Phippard D, Herold KC. Changes in T-cell subsets identify responders to FcR non-binding anti-CD3 mAb (teplizumab) in patients with Type 1 diabetes. European Journal of Immunology. PMID 26518356 DOI: 10.1002/eji.201545708  0.52
2015 Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP. β cell death and dysfunction during type 1 diabetes development in at-risk individuals. The Journal of Clinical Investigation. 125: 1163-73. PMID 25642774 DOI: 10.1172/JCI78142  0.52
2015 Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP. A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care. 38: 271-6. PMID 25519451 DOI: 10.2337/dc14-1813  0.52
2014 Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M. Analysis of β-cell death in type 1 diabetes by droplet digital PCR. Endocrinology. 155: 3694-8. PMID 25004096 DOI: 10.1210/en.2014-1150  0.52
2014 Vudattu NK, Waldron-Lynch F, Truman LA, Deng S, Preston-Hurlburt P, Torres R, Raycroft MT, Mamula MJ, Herold KC. Humanized mice as a model for aberrant responses in human T cell immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 193: 587-96. PMID 24943216 DOI: 10.4049/jimmunol.1302455  0.52
2014 Tooley JE, Herold KC. Biomarkers in type 1 diabetes: application to the clinical trial setting. Current Opinion in Endocrinology, Diabetes, and Obesity. 21: 287-92. PMID 24937037 DOI: 10.1097/MED.0000000000000076  0.52
2014 Akirav EM, Henegariu O, Preston-Hurlburt P, Schmidt AM, Clynes R, Herold KC. The receptor for advanced glycation end products (RAGE) affects T cell differentiation in OVA induced asthma. Plos One. 9: e95678. PMID 24759895 DOI: 10.1371/journal.pone.0095678  0.52
2014 Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP. Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care. 37: 979-84. PMID 24550217 DOI: 10.2337/dc13-2359  0.52
2014 Vudattu NK, Herold KC. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opinion On Biological Therapy. 14: 377-85. PMID 24517093 DOI: 10.1517/14712598.2014.881797  0.52
2014 Viehmann Milam AA, Maher SE, Gibson JA, Lebastchi J, Wen L, Ruddle NH, Herold KC, Bothwell AL. A humanized mouse model of autoimmune insulitis. Diabetes. 63: 1712-24. PMID 24478396 DOI: 10.2337/db13-1141  0.52
2014 Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, et al. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells. Cell Metabolism. 19: 109-21. PMID 24332968 DOI: 10.1016/j.cmet.2013.11.007  0.52
2014 Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC. Characterization of residual β cell function in long-standing type 1 diabetes. Diabetes/Metabolism Research and Reviews. 30: 154-62. PMID 24115337 DOI: 10.1002/dmrr.2478  0.52
2014 Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care. 37: 210-6. PMID 23939544 DOI: 10.2337/dc13-1169  0.52
2013 Herold KC. Restoring immune balance in type 1 diabetes. The Lancet. Diabetes & Endocrinology. 1: 261-3. PMID 24622404 DOI: 10.1016/S2213-8587(13)70123-2  0.52
2013 Vudattu NK, Herold KC. Delayed anti-CD3 therapy in a mouse heart transplant model induced tolerance and long-term survival of allograft: achieving tolerance. Immunotherapy. 5: 1173-6. PMID 24188671 DOI: 10.2217/imt.13.113  0.52
2013 Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP. Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes. 62: 4179-83. PMID 23863814 DOI: 10.2337/db13-0656  0.52
2013 Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 62: 3766-74. PMID 23835333 DOI: 10.2337/db13-0345  0.52
2013 Hagopian W, Ferry RJ, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 62: 3901-8. PMID 23801579 DOI: 10.2337/db13-0236  0.52
2013 Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clinical Immunology (Orlando, Fla.). 149: 268-78. PMID 23726024 DOI: 10.1016/j.clim.2013.05.001  0.52
2013 Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M, Preston-Hurlburt P, Herold KC, Hafler DA, O'Connor KC, Meffre E. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. The Journal of Clinical Investigation. 123: 2737-41. PMID 23676463 DOI: 10.1172/JCI68775  0.52
2013 Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (London, England). 381: 1905-15. PMID 23562090 DOI: 10.1016/S0140-6736(13)60023-9  0.52
2013 Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nature Reviews. Immunology. 13: 243-56. PMID 23524461 DOI: 10.1038/nri3422  0.52
2013 Hughes JW, Herold KC. Novel SIRT1 mutation linked to autoimmune diabetes in humans. Cell Metabolism. 17: 311-2. PMID 23473025 DOI: 10.1016/j.cmet.2013.02.014  0.52
2013 Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC. Immune therapy and β-cell death in type 1 diabetes. Diabetes. 62: 1676-80. PMID 23423576 DOI: 10.2337/db12-1207  0.52
2013 Sarikonda G, Sachithanantham S, Manenkova Y, Kupfer T, Posgai A, Wasserfall C, Bernstein P, Straub L, Pagni PP, Schneider D, Calvo TR, Coulombe M, Herold K, Gill RG, Atkinson M, et al. Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. Plos One. 8: e54712. PMID 23405091 DOI: 10.1371/journal.pone.0054712  0.52
2012 Sherwin R, Slayman C, Rockwell S, Herold K, Williams K, Carson R, Mane S, Seow H, Max J, Johnson T. Yale Center for Clinical Investigation: leveraging industry partnerships and research cores. Clinical and Translational Science. 5: 435-6. PMID 23253663 DOI: 10.1111/cts.12016  0.52
2012 Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 61: 2066-73. PMID 22688329 DOI: 10.2337/db11-1538  0.52
2012 Lebastchi J, Herold KC. Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harbor Perspectives in Medicine. 2: a007708. PMID 22675665 DOI: 10.1101/cshperspect.a007708  0.52
2012 Sosenko JM, Skyler JS, Herold KC, Palmer JP. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes. 61: 1331-7. PMID 22618768 DOI: 10.2337/db11-1660  0.52
2012 Czyzyk J, Henegariu O, Preston-Hurlburt P, Baldzizhar R, Fedorchuk C, Esplugues E, Bottomly K, Gorus FK, Herold K, Flavell RA. Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes. Journal of Immunology (Baltimore, Md. : 1950). 188: 6319-27. PMID 22593614 DOI: 10.4049/jimmunol.1200467  0.52
2012 Normandin MD, Petersen KF, Ding YS, Lin SF, Naik S, Fowles K, Skovronsky DM, Herold KC, McCarthy TJ, Calle RA, Carson RE, Treadway JL, Cline GW. In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 908-16. PMID 22573821 DOI: 10.2967/jnumed.111.100545  0.52
2012 Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM, Herold KC. RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. Plos One. 7: e34698. PMID 22509345 DOI: 10.1371/journal.pone.0034698  0.52
2012 Tooley JE, Waldron-Lynch F, Herold KC. New and future immunomodulatory therapy in type 1 diabetes. Trends in Molecular Medicine. 18: 173-81. PMID 22342807 DOI: 10.1016/j.molmed.2012.01.001  0.52
2012 Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, Mandrup-Poulsen T, Herold KC. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes. 61: 145-54. PMID 22043003 DOI: 10.2337/db11-1033  0.52
2012 Ablamunits V, Klebanov S, Giese SY, Herold KC. Functional human to mouse adipose tissue xenotransplantation. The Journal of Endocrinology. 212: 41-7. PMID 22007021 DOI: 10.1530/JOE-11-0201  0.52
2011 Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, Lizardi PM, Herold KC. Detection of β cell death in diabetes using differentially methylated circulating DNA. Proceedings of the National Academy of Sciences of the United States of America. 108: 19018-23. PMID 22074781 DOI: 10.1073/pnas.1111008108  0.52
2011 Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A. Effect of rituximab on human in vivo antibody immune responses. The Journal of Allergy and Clinical Immunology. 128: 1295-1302.e5. PMID 21908031 DOI: 10.1016/j.jaci.2011.08.008  0.52
2011 Herold KC, Bluestone JA. Type 1 diabetes immunotherapy: is the glass half empty or half full? Science Translational Medicine. 3: 95fs1. PMID 21832236 DOI: 10.1126/scitranslmed.3002981  0.52
2011 Yu L, Herold K, Krause-Steinrauf H, McGee PL, Bundy B, Pugliese A, Krischer J, Eisenbarth GS. Rituximab selectively suppresses specific islet antibodies Diabetes. 60: 2560-2565. PMID 21831969 DOI: 10.2337/db11-0674  0.52
2011 Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. Journal of Immunology (Baltimore, Md. : 1950). 187: 1998-2005. PMID 21775681 DOI: 10.4049/jimmunol.1100539  0.52
2011 Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, et al. Control of TH17 cells occurs in the small intestine. Nature. 475: 514-8. PMID 21765430 DOI: 10.1038/nature10228  0.52
2011 Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, ... ... Herold KC, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 378: 487-97. PMID 21719095 DOI: 10.1016/S0140-6736(11)60931-8  0.52
2011 Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (London, England). 378: 319-27. PMID 21714999 DOI: 10.1016/S0140-6736(11)60895-7  0.52
2011 Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nature Reviews. Drug Discovery. 10: 439-52. PMID 21629294 DOI: 10.1038/nrd3402  0.52
2011 Ablamunits V, Henegariu O, Preston-Hurlburt P, Herold KC. NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody. European Journal of Immunology. 41: 1832-42. PMID 21538351 DOI: 10.1002/eji.201041258  0.52
2011 Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes. 60: 1370-9. PMID 21525508 DOI: 10.2337/db10-1797  0.52
2011 Akirav EM, Baquero MT, Opare-Addo LW, Akirav M, Galvan E, Kushner JA, Rimm DL, Herold KC. Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose. Diabetes. 60: 876-83. PMID 21307078 DOI: 10.2337/db10-0793  0.52
2011 Kochar R, Herold KC. Prevention of T1DM: feeding the ultimate goal. Nature Reviews. Endocrinology. 7: 132-4. PMID 21301485 DOI: 10.1038/nrendo.2011.19  0.52
2011 Akirav EM, Ruddle NH, Herold KC. The role of AIRE in human autoimmune disease. Nature Reviews. Endocrinology. 7: 25-33. PMID 21102544 DOI: 10.1038/nrendo.2010.200  0.52
2010 Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. European Journal of Immunology. 40: 2891-901. PMID 21038470 DOI: 10.1002/eji.201040485  0.52
2010 Sosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Cuthbertson D, Cowie C, Herold K, Eisenbarth G, Palmer JP. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes. 59: 2386-9. PMID 20682683 DOI: 10.2337/db10-0534  0.52
2010 Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 464: 1293-300. PMID 20432533 DOI: 10.1038/nature08933  0.52
2010 Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity. 32: 488-99. PMID 20412759 DOI: 10.1016/j.immuni.2010.04.002  0.52
2010 Cernea S, Herold KC. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clinical Immunology (Orlando, Fla.). 134: 121-9. PMID 19837003 DOI: 10.1016/j.clim.2009.09.005  0.52
2009 Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes/Metabolism Research and Reviews. 25: 694-704. PMID 19771545 DOI: 10.1002/dmrr.1002  0.52
2009 Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes. 58: 2588-95. PMID 19675135 DOI: 10.2337/db09-0249  0.52
2009 Begum S, Chen W, Herold KC, Papaioannou VE. Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors. Endocrinology. 150: 4512-20. PMID 19589867 DOI: 10.1210/en.2009-0287  0.52
2009 Lepus CM, Gibson TF, Gerber SA, Kawikova I, Szczepanik M, Hossain J, Ablamunits V, Kirkiles-Smith N, Herold KC, Donis RO, Bothwell AL, Pober JS, Harding MJ. Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Human Immunology. 70: 790-802. PMID 19524633 DOI: 10.1016/j.humimm.2009.06.005  0.52
2009 Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clinical Immunology (Orlando, Fla.). 132: 166-73. PMID 19443276 DOI: 10.1016/j.clim.2009.04.007  0.52
2009 Waldron-Lynch F, Herold KC. Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Endocrinology and Metabolism Clinics of North America. 38: 303-17, viii. PMID 19328413 DOI: 10.1016/j.ecl.2009.01.005  0.52
2009 Kaufman A, Herold KC. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes/Metabolism Research and Reviews. 25: 302-6. PMID 19319985 DOI: 10.1002/dmrr.933  0.52
2009 Waldron-Lynch F, Herold KC. Continuous glucose monitoring: long live the revolution! Nature Clinical Practice. Endocrinology & Metabolism. 5: 82-3. PMID 19092785 DOI: 10.1038/ncpendmet1044  0.52
2009 Chen W, Begum S, Opare-Addo L, Garyu J, Gibson TF, Bothwell AL, Papaioannou VE, Herold KC. Promotion of beta-cell differentiation in pancreatic precursor cells by adult islet cells. Endocrinology. 150: 570-9. PMID 18845629 DOI: 10.1210/en.2008-1009  0.52
2008 Waldron-Lynch F, von Herrath M, Herold KC. Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass. Novartis Foundation Symposium. 292: 146-55; discussion 1. PMID 19203097  0.52
2008 Ablamunits V, Bisikirska BC, Herold KC. Human regulatory CD8 T cells. Annals of the New York Academy of Sciences. 1150: 234-8. PMID 19120302 DOI: 10.1196/annals.1447.000  0.52
2008 Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 57: 2883-8. PMID 18971435 DOI: 10.2337/db07-1817  0.52
2008 Ablamunits V, Herold KC. Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). Human Immunology. 69: 732-6. PMID 18817833 DOI: 10.1016/j.humimm.2008.08.290  0.52
2008 Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, Herold KC. RAGE ligation affects T cell activation and controls T cell differentiation. Journal of Immunology (Baltimore, Md. : 1950). 181: 4272-8. PMID 18768885  0.52
2008 Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Annals of the New York Academy of Sciences. 1126: 7-13. PMID 18448789 DOI: 10.1196/annals.1433.056  0.52
2008 Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. Nature Clinical Practice. Endocrinology & Metabolism. 4: 334-43. PMID 18446141 DOI: 10.1038/ncpendmet0832  0.52
2008 King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, Atkinson MA, Wasserfall C, Herold KC, Woodland RT, Schmidt MR, Woda BA, Thompson MJ, Rossini AA, Greiner DL. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clinical Immunology (Orlando, Fla.). 126: 303-14. PMID 18096436 DOI: 10.1016/j.clim.2007.11.001  0.52
2007 Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): Weaving tangled webs within the inflammatory response Current Molecular Medicine. 7: 743-751. PMID 18331232 DOI: 10.2174/156652407783220714  0.52
2007 Clynes R, Herold K, Schmidt AM. RAGE: Exacting a toll on the host in response to polymicrobial sepsis and Listeria monocytogenes Critical Care. 11. PMID 18190725 DOI: 10.1186/cc6193  0.52
2007 Moser B, Desai DD, Downie MP, Chen Y, Shi FY, Herold K, Schmidt AM, Clynes R. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo Journal of Immunology. 179: 8051-8058. PMID 18056345  0.52
2007 Page KA, Dejardin S, Kahn CR, Kulkarni RN, Herold KC, Inzucchi SE. A patient with type B insulin resistance syndrome, responsive to immune therapy. Nature Clinical Practice. Endocrinology & Metabolism. 3: 835-40. PMID 18026162 DOI: 10.1038/ncpendmet0693  0.52
2007 Von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nature Reviews Immunology. 7: 988-994. PMID 17982429 DOI: 10.1038/nri2192  0.52
2007 Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 148: 5136-44. PMID 17673522 DOI: 10.1210/en.2007-0358  0.52
2007 Herold K, Moser B, Chen Y, Zeng S, Shi FY, Ramasamy R, Emond J, Clynes R, Schmidt AM. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: Inflammatory signals gone awry in the primal response to stress Journal of Leukocyte Biology. 82: 204-212. PMID 17513693 DOI: 10.1189/jlb.1206751  0.52
2007 Ablamunits V, Sherry NA, Kushner JA, Herold KC. Autoimmunity and β cell regeneration in mouse and human type 1 diabetes: The peace is not enough Annals of the New York Academy of Sciences. 1103: 19-32. PMID 17376841 DOI: 10.1196/annals.1394.006  0.52
2007 King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, Atkinson M, Wasserfall C, Herold K, Mordes JP, Rossini AA, Greiner DL. Development of new-generation HU-PBMC-NOD/SCID mice to study human islet alloreactivity Annals of the New York Academy of Sciences. 1103: 90-93. PMID 17376822 DOI: 10.1196/annals.1394.011  0.52
2007 Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care. 30: 38-42. PMID 17192330 DOI: 10.2337/dc06-1615  0.52
2007 Witkowski P, Herold KC. Islet transplantation for type 1 diabetes - Where should we go? Nature Clinical Practice Endocrinology and Metabolism. 3: 2-3. PMID 17179921 DOI: 10.1038/ncpendmet0369  0.52
2006 Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AMB, Herold KC. Effects of autoimmunity and immune therapy on β-cell turnover in type 1 diabetes Diabetes. 55: 3238-3245. PMID 17130466 DOI: 10.2337/db05-1034  0.52
Show low-probability matches.